The Annals of pharmacotherapy · 2024
Travoprost Intracameral Implant: A Review on the Novel Treatment Modality for Open-Angle Glaucoma and Ocular Hypertension.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huston Jessica, Paauw Mark, Orey Dontia, Centner Aliya, Hasan Azeem, Shetty Rajesh, Freidl Kathryn, Goldfaden Rebecca
Аннотация
OBJECTIVE: This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of travoprost, intracameral implant, a treatment for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.
DATA SOURCES: A literature search was conducted from drug discovery until September 2024 through PubMed, MEDLINE, and National Institutes of Health Clinical Trials Registry utilizing the following search terms: iDose, travoprost, intracameral implant, OTX-TIC, open-angle glaucoma, and ocular hypertension.
STUDY SELECTION AND DATA EXTRACTION: All relevant English-language studies, or studies that could be appropriately translated into English, containing the pharmacology, pharmacokinetics, safety, and efficacy of travoprost intracameral implant were selected for review.
DATA SYNTHESIS: Travoprost implants showed significant reductions in IOP compared with other treatment options with fewer limitations often associated with topical medications resulting in travoprost implant patients favoring reduced concomitant use of topical IOP-lowering medications (with 81% of patients being medication free).Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:Due to limited compliance with topical treatment modalities, the travoprost implant presents a promising alternative pathway for drug delivery. With a duration of 3 years and removal of the need for patient dexterity and application compliance, the travoprost implant serves an unmet need for patients and prescribers.
CONCLUSION: Travoprost intracameral implant is a safe and effective delivery system for intracameral travoprost administration for patients with OAG or ocular hypertension.
DATA SOURCES: A literature search was conducted from drug discovery until September 2024 through PubMed, MEDLINE, and National Institutes of Health Clinical Trials Registry utilizing the following search terms: iDose, travoprost, intracameral implant, OTX-TIC, open-angle glaucoma, and ocular hypertension.
STUDY SELECTION AND DATA EXTRACTION: All relevant English-language studies, or studies that could be appropriately translated into English, containing the pharmacology, pharmacokinetics, safety, and efficacy of travoprost intracameral implant were selected for review.
DATA SYNTHESIS: Travoprost implants showed significant reductions in IOP compared with other treatment options with fewer limitations often associated with topical medications resulting in travoprost implant patients favoring reduced concomitant use of topical IOP-lowering medications (with 81% of patients being medication free).Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:Due to limited compliance with topical treatment modalities, the travoprost implant presents a promising alternative pathway for drug delivery. With a duration of 3 years and removal of the need for patient dexterity and application compliance, the travoprost implant serves an unmet need for patients and prescribers.
CONCLUSION: Travoprost intracameral implant is a safe and effective delivery system for intracameral travoprost administration for patients with OAG or ocular hypertension.